Arexis AB announced the completion of a successful phase II clinical
trial around their novel human enzyme replacement therapy for the treatment
of fat mal-absorption in patients with cystic fibrosis.
Cystic fibrosis is a disease involving severe fat mal-absorption due
to pancreatic dysfunction that affects in excess of 100,000 patients
worldwide.
These patients suffer deficiencies in production of key digestive enzymes,
and as a result fail to make use of important nutrients of their diet.
Arexis's study, which was conducted at Sahlgrenska University Hospital
in Gothenburg, shows that if cystic fibrosis patients are supplemented
with the enzyme BSSL (bile salt-stimulated lipase), lipid uptake is
more rapid and fully restored.
Source: AREXIS AB; “Novel therapy has positive
effect on lipid uptake in cystic fibrosis patients”NewsRx.net,
October 10, 2004 - http://www.esiason.org/article.php?wh=47
